JP2022529502A5 - - Google Patents

Info

Publication number
JP2022529502A5
JP2022529502A5 JP2021562989A JP2021562989A JP2022529502A5 JP 2022529502 A5 JP2022529502 A5 JP 2022529502A5 JP 2021562989 A JP2021562989 A JP 2021562989A JP 2021562989 A JP2021562989 A JP 2021562989A JP 2022529502 A5 JP2022529502 A5 JP 2022529502A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
antibody
acid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021562989A
Other languages
English (en)
Japanese (ja)
Other versions
JP7602485B2 (ja
JP2022529502A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/029531 external-priority patent/WO2020219681A1/en
Publication of JP2022529502A publication Critical patent/JP2022529502A/ja
Publication of JP2022529502A5 publication Critical patent/JP2022529502A5/ja
Application granted granted Critical
Publication of JP7602485B2 publication Critical patent/JP7602485B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021562989A 2019-04-23 2020-04-23 抗ｃｄ３８抗体および製剤 Active JP7602485B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962837518P 2019-04-23 2019-04-23
US62/837,518 2019-04-23
US201962859699P 2019-06-10 2019-06-10
US62/859,699 2019-06-10
EP20305145 2020-02-17
EP20305146.1 2020-02-17
EP20305146 2020-02-17
EP20305145.3 2020-02-17
PCT/US2020/029531 WO2020219681A1 (en) 2019-04-23 2020-04-23 Anti-cd38 antibodies and formulations

Publications (3)

Publication Number Publication Date
JP2022529502A JP2022529502A (ja) 2022-06-22
JP2022529502A5 true JP2022529502A5 (https=) 2023-05-01
JP7602485B2 JP7602485B2 (ja) 2024-12-18

Family

ID=70739160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021562989A Active JP7602485B2 (ja) 2019-04-23 2020-04-23 抗ｃｄ３８抗体および製剤

Country Status (15)

Country Link
EP (1) EP3958898A1 (https=)
JP (1) JP7602485B2 (https=)
KR (1) KR20220003562A (https=)
CN (2) CN120757645A (https=)
AU (1) AU2020261039A1 (https=)
BR (1) BR112021021060A2 (https=)
CA (1) CA3137365A1 (https=)
CO (1) CO2021015462A2 (https=)
IL (1) IL287477A (https=)
MA (1) MA55761A (https=)
MX (1) MX2021012967A (https=)
MY (1) MY206426A (https=)
SG (1) SG11202111602YA (https=)
TW (1) TWI878289B (https=)
WO (1) WO2020219681A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024546152A (ja) * 2021-12-16 2024-12-17 上海宝済薬業股▲ふん▼有限公司 免疫グロブリン分解酵素による切断に対抗するＦｃ変異体
WO2024023843A1 (en) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited A pharmaceutical formulation of a therapeuticantibody and preparations thereof
WO2025245526A1 (en) * 2024-05-24 2025-11-27 Research Institute At Nationwide Children's Hospital Cd-38 protein binding compositions and methods related thereto
CN120535629B (zh) * 2025-04-22 2026-01-23 西安市中心血站（陕西省血液中心） 一种用于抑制cd38单抗对输血相容性检测干扰的抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005277831B2 (en) 2004-07-10 2012-11-22 The Institute For Cancer Research Genetically modified human natural killer cell lines
EP2471813B1 (en) * 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP3559049B1 (en) * 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
WO2016022589A2 (en) * 2014-08-08 2016-02-11 The Regents Of The University Of California Methods for treating multiple myeloma
CA3004152C (en) * 2015-11-03 2024-04-16 Janssen Biotech, Inc. Subcutaneous formulations of anti-cd38 antibodies and their uses
EP3479819B1 (en) * 2016-06-30 2024-01-24 Celltrion Inc. Stable liquid pharmaceutical preparation
JP2020518598A (ja) * 2017-05-02 2020-06-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 単独およびプログラム死受容体１（ｐｄ−１）抗体と組み合わされた抗ｃｔｌａ４抗体の安定な製剤、ならびにその使用方法
JP2020535181A (ja) * 2017-09-29 2020-12-03 ヤンセン バイオテツク，インコーポレーテツド 低用量抗体組成物を安定化する新規製剤
CN108752475B (zh) * 2018-06-14 2021-07-30 北京智仁美博生物科技有限公司 抗人cd38抗体及其用途

Similar Documents

Publication Publication Date Title
US20260115254A1 (en) Immune-cell targeted bispecific chimeric proteins and uses thereof
US20240025980A1 (en) Therapeutic targeting of non-cellular structures
JP2022529502A5 (https=)
US11236141B2 (en) Targeted mutant interferon-beta and uses thereof
US10858425B2 (en) Pan-ELR+ CXC chemokine antibodies
CA2901468C (en) Pan-elr+ cxc chemokine antibodies
JP2021533204A5 (https=)
RS63238B1 (sr) Kombinovana terapija sa anti-cd19 antitelom i azotnim senfom
CN106573059A (zh) 接受过抗TNF‑α抗体疗法的银屑病患者的治疗方法
CA3227386A1 (en) Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications
RU2021133923A (ru) Антитела к cd38 и составы
CN1291998C (zh) Nkg2d受体的配体及其应用
CN1128810C (zh) 防治肝病的鲨鱼肝多肽结构及纯化
TW202423968A (zh) Ｃｄ３８結合融合蛋白組合療法
JP2024501659A (ja) 急性呼吸窮迫症候群を治療又は防止するための方法
CN118021955A (zh) 用于治疗il-17a介导的疾病或病症的方法和组合物
HK1212714B (en) Pan-elr+ cxc chemokine antibodies